Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021 the American Cancer Society projected 1.9 million new cancer cases and 608,570 cancer deaths in the United States. Breast cancer accounted for an…
BDC-1001, a HER2-targeted ISAC consisting of a trastuzumab biosimilar covalently linked to a proprietary TLR7/8 agonist, was administered in dose escalation to…
Bolt Biotherapeutics is laying off 50% of its workforce after the company's research collaboration with Genmab failed to advance any candidates beyond…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Genmab and Bolt entered an oncology R&D collaboration combining Genmab's antibody and bispecific platforms with Bolt's Boltbody ISAC technology. Bolt received $10M upfront plus a $15M equity investment and is eligible for up to $285M per program for up to three Genmab-developed candidates plus tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genmab A/S / Bolt Biotherapeutics, Inc. (this deal) | 2021 | $880M | — |
| Genmab A/S / ProfoundBio Inc. | 2024 | $1.8B | 64 |
| Genmab A/S / Merus N.V. | 2025 | $8.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2021 deals · Genmab A/S deals · Oncology deals